Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 30

recruiting
3 987
countries
28
conditions
2 109

775 trials match your criteria

Study on IMVT-1402 for Patients with Active Cutaneous Lupus Erythematosus

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart

Alopecia areata

Not recruiting

Study on the Effects of Ritlecitinib in Patients Aged 12 and Older with Alopecia Areata

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years

Study of ISIS 678354 for Patients with Severe High Triglycerides

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt

Psoriasis

Not recruiting

Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Envudeucitinib

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast

Study on the Effects and Safety of Ginkgo Biloba Extract in Patients with Cognitive Impairment After COVID-19

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:REFINED AND QUANTIFIED DRY EXTRACT OF GINKGO BILOBA LEAVES (35-67:1) QUANTIFIED TO 22.0 TO 27.0 % OF FLAVONOIDS EXPRESSED AS FLAVONE GLYCOSIDES, 2.8 TO 3.4 % OF GINKGOLIDES A, B AND C, AND 2.6 TO 3.2 % OF BILOBALIDE. EXTRACTION SOLVENT: ACETONE 60% (M/M)

Asthma

Not recruiting

Study on the Effects of Lunsekimig (SAR443765) in Adults with High-Risk Asthma Not Eligible for Biologic Treatment

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen

Dermatitis atopic

Not recruiting

Study on the Safety and Effectiveness of APG777 for Patients with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:APG777

Study Comparing Ivonescimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study on the Effectiveness and Safety of Lanifibranor for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis Stages F2/F3

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lanifibranor

Dermatitis atopic

Not recruiting

Study on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nemolizumab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.